Malta - inglise - Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - voriconazole - powder for solution for infusion - voriconazole 200 mg - antimycotics for systemic use

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - voriconazole - powder for solution for infusion - 200 milligram(s) - voriconazole

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; maize starch; croscarmellose sodium; povidone; silicon dioxide; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole is indicated for treatment of the following fungal infections:invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

vetoquinol usa, inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz), chloroxylenol (unii: 0f32u78v2q) (chloroxylenol - unii:0f32u78v2q) - miconazole nitrate 20 mg in 1 ml - vetoquinol sebozole™ shampoo is uniquely formulated to provide antimicrobial, antifungal and antiseborrheic agents for optimal therapeutic effectiveness. indications for use: for dermatological conditions associated with infections responsive to miconazole nitrate, salicylic acid and chloroxylenol.

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - voriconazole - film coated tablet - 200 milligram - voriconazole

Malta - inglise - Medicines Authority

actavis group ptc ehf - voriconazole - film-coated tablet - voriconazole 50 mg - antimycotics for systemic use

Malta - inglise - Medicines Authority

actavis group ptc ehf - voriconazole - film-coated tablet - voriconazole 200 mg - antimycotics for systemic use

Malta - inglise - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - voriconazole - film-coated tablet - voriconazole 200 mg - antimycotics for systemic use

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - voriconazole 200mg - film coated tablet - 200 mg - active: voriconazole 200mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate maize starch opadry white 33k18618 povidone pregelatinised maize starch - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.